CRNX (STOCKS)
Crinetics Pharmaceuticals, Inc.
$84.440000
-0.020000 (-0.02%)
Prev close: $84.460000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- R. Scott Struthers
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $9,032.07M
- Employees
- 437
- P/E (TTM)
- -16.74
- P/B (TTM)
- 7.50
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
4
Buy
14
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-1.14 | $-1.23 | +0.0932 | +7.56% |
|
Mar 2026 (Q1)
|
$-1.23 | $-1.26 | +0.0317 | +2.51% |
|
Dec 2025 (Q4)
|
$-1.29 | $-1.39 | +0.1048 | +7.51% |
|
Sep 2025 (Q3)
|
$-1.38 | $-1.28 | -0.0993 | -7.75% |
Financial Statements
| Revenues | $42.16M |
| Benefits Costs and Expenses | $567.72M |
| Cost Of Revenue | $1.43M |
| Costs And Expenses | $619.35M |
| Nonoperating Income/Loss | $47.66M |
| Operating Expenses | $589.82M |
| Depreciation and Amortization | $4.24M |
| Research and Development | $375.45M |
| Operating Income/Loss | -$549.09M |
| Income/Loss From Continuing Operations After Tax | -$501.61M |
| Income/Loss From Continuing Operations Before Tax | -$525.56M |
| Net Income/Loss | -$501.61M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$501.61M |
| Net Income/Loss Available To Common Stockholders, Basic | -$501.61M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.04 |
| Diluted Earnings Per Share | -$5.04 |
| Basic Average Shares | 304,224,000 |
| Diluted Average Shares | 304,224,000 |
| Assets | $1.32B |
| Current Assets | $1.24B |
| Cash | $1.20B |
| Inventory | $3.49M |
| Other Current Assets | $40.87M |
| Noncurrent Assets | $77.52M |
| Fixed Assets | $13.07M |
| Other Non-current Assets | $64.45M |
| Liabilities | $129.92M |
| Current Liabilities | $79.92M |
| Accounts Payable | $13.25M |
| Other Current Liabilities | $66.67M |
| Noncurrent Liabilities | $50.01M |
| Equity | $1.19B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.19B |
| Liabilities And Equity | $1.32B |
| Net Cash Flow From Operating Activities | -$422.52M |
| Net Cash Flow From Operating Activities, Continuing | -$422.52M |
| Net Cash Flow From Investing Activities | -$4.15M |
| Net Cash Flow From Investing Activities, Continuing | -$4.15M |
| Net Cash Flow From Financing Activities | $427.92M |
| Net Cash Flow From Financing Activities, Continuing | $427.92M |
| Net Cash Flow | $1.25M |
| Net Cash Flow, Continuing | $1.25M |
| Comprehensive Income/Loss | -$506.24M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$506.24M |
| Other Comprehensive Income/Loss | -$4.63M |
| Other Comprehensive Income/Loss Attributable To Parent | -$4.63M |